Impact of tuberculosis on HIV-1 replication, diversity, and disease progression

AIDS Reviews

Volumn 4, Issue 3, 2002, Pages 165-176

  Collins, Kalonji R ^a   Quiñones Mateu, Miguel E ^a   Toossi, Zahra ^a   Arts, Eric J ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Evolution; Genetic variability; HIV; Tuberculosis

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; CHEMOKINE; CYTOKINE; INTERLEUKIN 1; ISONIAZID; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; RNA DIRECTED DNA POLYMERASE; TUMOR NECROSIS FACTOR ALPHA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE EXACERBATION; DISEASE PREDISPOSITION; DISEASE SEVERITY; DRUG EXPOSURE; DRUG POTENTIATION; EVOLUTION; GENETIC VARIABILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOREGULATION; IMMUNOSTIMULATION; INCIDENCE; LEUKOCYTE MIGRATION; LUNG TUBERCULOSIS; LYMPHOCYTE; LYMPHOCYTE COUNT; LYMPHOCYTE MIGRATION; MACROPHAGE; MACROPHAGE MIGRATION; MICROBIAL DIVERSITY; MONOCYTE; MORTALITY; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; OPPORTUNISTIC INFECTION; PATHOGENESIS; PHYLOGENY; PREVALENCE; PUBLIC HEALTH; REVIEW; TUBERCULOSIS; TUBERCULOUS PLEURISY; VIRUS LOAD; VIRUS REPLICATION;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; DISEASE PROGRESSION; HIV INFECTIONS; HIV-1; HUMANS; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS, PULMONARY; VARIATION (GENETICS); VIRUS REPLICATION;

EID: 0036630033     PISSN: 11396121     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (140)

1. UNAIDS. AIDS Epidemic Update. Geneva, Switzerland: UN-AIDS/WHO, 2001.
2. Bloom BR, Murray CJ. Tuberculosis: commentary on a re-emergent killer. Science 1992;257:1055-64.
3. CDC. Reported Tuberculosis in the United States, 2000 Atlanta, GA: Center for Diseases Control, 2000.
4. WHO. Global Tuberculosis Control. WHO Report 2001. Geneva, Switzerland. 2001.
5. Goletti D, Weissman D, Jackson R, et al. Effect of Mycobacterium tuberculosis on HIV replication. Role of immune activation. J Immunol 1996;157:1271-8.
6. Collins K, Mayanja-Kizza H, Sullivan B, et al. Greater diversity of HIV-1 quasispecies in HIV-infected individuals with active tuberculosis. J Acquir Immune Defic Syndr 2000;24:408-17.
7. Toossi Z, Mayanja-Kizza H, Hirsch C, et al. Impact of tuberculosis (TB) on HIV-1 activity in dually infected patients. Clin Exp Immunol 2001;123:233-8.
8. Toossi Z, Xia L, Wu M, Salvekar A. Transcriptional activation of HIV by Mycobacterium tuberculosis in human monocytes. Clin Exp Immunol 1999;117:324-30.
9. Toossi Z, Sierra-Madero J, Blinkhorn R, Mettler M, Rich E. Enhanced susceptibility of blood monocytes from patients with pulmonary tuberculosis to productive infection with HIV type 1. J Exp Med 1993;177:1511-6.
10. Nakata K, Rom W, Honda Y, et al. Mycobacterium tuberculosis enhances human immunodeficiency virus-1 replication in the lung. Am J Respir Crit Care Med 1997;155:996-1003.
11. Collins K, Quiñones-Mateu M, et al. HIV-1 quasispecies at the sites of Mycobacterium tuberculosis infection contribute to systemic HIV-1 heterogeneity. J Virol 2002;76:1697-706.
12. Toossi Z, Johnson J, Kanost R, et al. Increased replication of HIV-1 at sites of Mycobacterium tuberculosis infection: potential mechanisms of viral activation. J Acquir Immune Defic Syndr 2001;28:1-8.
13. Vanham G, Edmonds K, Qing L, et al. Generalized immune activation in pulmonary tuberculosis: co-activation with HIV infection. Clin Exp Immunol 1996;103:30-34.
14. Hughes M, Ball N, Love D, et al. Disseminated Mycobacterium genavense infection in a HIV-positive cat. J Feline Med Surg 1999;1:23-9.
15. VanLeeuwen J, Keefe G, Tremblay R, Power C, Wichtel J. Seroprevalence of infection with Mycobacterium avium subspecies paratuberculosis, bovine leukemia virus, and bovine viral diarrhea virus in maritime Canada dairy cattle. Can Vet J 2001;42:193-8.
16. Coffin J, Hughes S, Varmus H. Retroviruses. Plainview, NY: Cold Spring Harbor Laboratory Press, xv, 843.
17. Brelot A, Alizon M. HIV-1 entry and how to block it. AIDS 2001;15(Suppl 5):3-11.
18. Eckert D, Kim P. Mechanisms of viral membrane fusion and its inhibition. Annu Rev Biochem 2001;70:777-810.
19. Telesnitsky A, Goff S. Reverse transcriptase and the generation of retroviral DNA. In: Coffin JM, Hughes SH, Varmus HE, eds. Retroviruses. Cold Spring Harbor, NY: Cold Spring Harbor Lab. Press 1997;121-60.
20. Starcich B, Ratner L, Josephs S, et al. Characterization of long terminal repeat sequences of HTLV-III. Science 1985;227:538-40.
21. Nabel G, Baltimore D. An inducible transcription factor activates expression of HIV in T cells. Nature 1987;326:711-3.
22. Okamoto T, Matsuyama T, Mori S, et al. Augmentation of HIV type 1 gene expression by tumor necrosis factor alpha. AIDS Res Hum Retroviruses 1989;5:131-8.
23. Kobayashi N, Hamamoto Y, Koyanagi Y, Chen I, Yamamoto N. Effect of interleukin-1 on the augmentation of HIV expression. Biochem Biophys Res Commun 1989;165:715-21.
24. Laspia M, Rice A, Matthews M. HIV-1 Tat protein increases transcriptional initiation and stabilizes elongation. Cell 1989;59:283-92.
25. Miller C, McChesney M, Moore P. Langerhans cells, macrophages and lymphocyte subsets in the cervix and vagina of rhesus macaques. Lab Invest 1992;67:628-34.
26. Hu J, Gardner M, Miller C. Simian immunodeficiency virus rapidly penetrates the cervicovaginal mucosa after intravaginal inoculation and infects intraepithelial dendritic cells. J Virol 2000;74:6087-95.
27. Cameron P, Pope M, Granelli-Piperno A, Steinman R. Dendritic cells and the replication of HIV-1. J Leukoc Biol 1996;59:158-71.
28. Spira A, Marx P, Patterson B, et al. Cellular targets of infection and route of viral dissemination after an intravaginal inoculation of simian immunodeficiency virus into rhesus macaques. J Exp Med 1996;183:215-25.
29. Cameron P, Freudenthal P, Barker J, Gezelter S, Inaba K, Steinman R. Dendritic cells exposed to HIV type 1 transmit a vigorous cytopathic infection to CD4+ T cells. Science 1992;257:383-7.
30. Chakrabarti L, Isola P, Cumont M, et al. Early stages of simian immunodeficiency virus infection in lymph nodes. Evidence for high viral load and successive populations of target cells. Am J Pathol 1994;144:1226-37.
31. Schacker T, Collier A, Hughes J, Shea T, Corey L. Clinical and epidemiologic features of primary HIV infection. Ann Intern Med 1996;125:257-64.
32. Gaines H, von Sydow M, Pehrson P, Lundbegh P. Clinical picture of primary HIV infection presenting as a glandular-fever-like illness. BMJ 1988;297:1363-8.
33. Quinn T. Acute primary HIV infection. Jama 1997;278:58-62.
34. Clark S, Saag M, Decker W, et al. High titers of cytopathic virus in plasma of patients with symptomatic primary HIV-1 infection. N Engl J Med 1991;324:954-60.
35. Daar E, Moudgil T, Meyer R, Ho D. Transient high levels of viremia in patients with primary HIV type 1 infection. N Engl J Med 1991;324:961-4.
36. Pilcher C, Shugars D, Fiscus S, et al. HIV in body fluids during primary HIV infection: implications for pathogenesis, treatment and public health. AIDS 2001;15:837-45.
37. Koup R, Safrit J, Cao Y, et al. Temporal association of cellular immune responses with the initial control of viremia in primary HIV type 1 syndrome. J Virol 1994;68:4650-5.
38. Mellors J, Rinaldo C Jr., Gupta P, White R, Todd J, Kingsley L. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 1996;272:1167-70.
39. Lubaki N, Shepherd M, Brookmeyer R, et al. HIV-1-specific cytolytic T-lymphocyte activity correlates with lower viral load, higher CD4 count, and CD8+CD38-DR- phenotype: comparison of statistical methods for measurement. J Acquir Immune Defic Syndr 1999;22:19-30.
40. Borrow P, Lewicki H, Hahn B, Shaw G, Oldstone M. Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary HIV type 1 infection. J Virol 1994;68:6103-10.
41. Demarest J, Jack N, Cleghorn F, et al. Immunologic and virologic analyses of an acutely HIV type 1-infected patient with extremely rapid disease progression. AIDS Res Hum Retroviruses 2001;17:1333-44.
42. Propato A, Schiaffella E, Vicenzi E, et al. Spreading of HIV-specific CD8+ T-cell repertoire in long-term nonprogressors and its role in the control of viral load and disease activity. Hum Immunol 2001;62:561-76.
43. Rosenberg E, LaRosa L, Flynn T, Robbins G, Walker B. Characterization of HIV-1-specific T-helper cells in acute and chronic infection. Immunol Lett 1999;66:89-93.
44. Blankson J, Persaud D, Siliciano R. The challenge of viral reservoirs in HIV-1 infection. Annu Rev Med 2002;53:557-93.
45. Chun T, Carruth L, Finzi D, et al. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature 1997;387:183-8.
46. Ostrowski M, Chun T, Justement S, et al. Both memory and CD45RA+/CD62L+ naïve CD4(+) T cells are infected in HIV type 1-infected individuals. J Virol 1999;73:6430-5.
47. Crowe S. Role of macrophages in the pathogenesis of HIV infection. Aust N Z J Med 1995;25:777-83.
48. Valentin A, Rosati M, Patenaude D, et al. Persistent HIV-1 infection of natural killer cells in patients receiving highly active antiretroviral therapy. Proc Natl Acad Sci USA 2002;99:7015-20.
49. Smith D, Wiegeshaus E, Navalkar R, Grover A. Host-parasite relationships in experimental airborne tuberculosis. I. Preliminary studies in BCG-vaccinated and non-vaccinated animals. J Bacteriol 1965;91:718-24.
50. Hirsch C, Ellner J, Russell D, Rich E. Complement receptor-mediated uptake and tumor necrosis factor-alpha-mediated growth inhibition of Mycobacterium tuberculosis by human alveolar macrophages. J Immunol 1994;152:743-53.
51. Orme I, Cooper A. Cytokine/chemokine cascades in immunity to tuberculosis. Immunol Today 1999;20:307-12.
52. Toossi Z. The inflammatory response in Mycobacterium tuberculosis infection. Arch Immunol Ther Exp (Warsz) 2000;48:513-9.
53. Tsukaguchi K, Balaji K, Boom W. CD4+ alpha beta T cell and gamma delta T cell responses to Mycobacterium tuberculosis. Similarities and differences in Ag recognition, cytotoxic effector function, and cytokine production. J Immunol 1995;154:1786-96.
54. Adams D. The granulomatous inflammatory response. A review. Am J Pathol 1976;84:164-91.
55. Dannenberg A Jr. Immune mechanisms in the pathogenesis of pulmonary tuberculosis. Rev Infect Dis 1989;11 (Suppl 2):369-78.
56. Raviglione M, Snider D Jr., Kochi A. Global epidemiology of tuberculosis. Morbidity and mortality of a worldwide epidemic. JAMA 1995;273:220-6.
57. Dolin P, Kochi A. Global tuberculosis incidence and mortality during 1990-2000. Bull World Health Organ 1994;72:213-20.
58. Di Perri G, Cruciani M, Danzi M, et al. Nosocomial epidemic of active tuberculosis among HIV-infected patients. Lancet 1989;2:1502-4.
59. Selwyn P, Hartel D, Lewis V, et al. A prospective study of the risk of tuberculosis among intravenous drug users with HIV infection. N Engl J Med 1989;320:545-50.
60. MMWR. Tuberculosis and acquired immunodeficiency syndrome New York City. MMWR Morb Mortal Wkly Rep 1987;36:785-90, 795.
61. Barnes P, Bloch A, Davidson P, Snider D. Tuberculosis in patients with human immunodeficiency virus infection. N Engl J Med 1991;324:1644-50.
62. Chretien J. Tuberculosis and HIV. The cursed duet. Bull Int Union Tuberc Lung Dis 1990;65:25-8.
63. Nambuya A, Sewankambo N, Mugerwa J, Goodgame R, Lucas S. Tuberculous lymphadenitis associated with HIV in Uganda. J Clin Pathol 1988;41:93-6.
64. Lucas D, Gill J, Nelson M, Soni N. HIV and acute fulminant infection. Hosp Med 1999;60:680-1.
65. Law K, Jagirdar J, Weiden M, Bodkin M, Rom W. Tuberculosis in HIV-positive patients: cellular response and immune activation in the lung. Am J Respir Crit Care Med 1996;153:1377-84.
66. Zhang M, Gong J, Iyer D, Jones B, Modlin R, Barnes P. T cell cytokine responses in persons with tuberculosis and HIV infection. J Clin Invest 1994;94:2435-42.
67. Whalen C, Horsburgh C, Hom D, Lahart C, Simberkoff M, Ellner J. Accelerated course of HIV infection after tuberculosis. Am J Respir Crit Care Med 1995;151:129-135.
68. Pape J, Jean S, Ho J, Hafner A, Johnson W. Effect of isoniazid prophylaxis on incidence of active tuberculosis and progression of HIV infection. Lancet 1993;342:268-72.
69. Whalen C, Nsubuga P, Okwera A, et al. Impact of pulmonary tuberculosis on survival of HIV-infected adults: a prospective epidemiologic study in Uganda. AIDS 2000;14:1219-28.
70. Lawn S, Butera S. Incorporation of HLA-DR into the envelope of HIV type 1 in vivo: correlation with stage of disease and presence of opportunistic infection. J Virol 2000;74:10256-9.
71. Zhang Y, Nakata K, Weiden M, Rom W. Mycobacterium tuberculosis enhances HIV-1 replication by transcriptional activation at the long terminal repeat. J Clin Invest 1995;95:2324-31.
72. Lederman M, Georges D, Kusner D, et al. Mycobacterium tuberculosis and its purified protein derivative activate expression of the HIV. J Acquir Immune Defic Syndr 1994;7:727-33.
73. Hirsch C, Toossi Z, Johnson J, et al. Augmentation of apoptosis and interferon-gamma production at sites of active Mycobacterium tuberculosis infection in human tuberculosis. J Infect Dis 2001;183:779-88.
74. Mayanja-Kizza H, Johnson J, Hirsch C, et al. Macrophage-activating cytokines in HIV type 1-infected and -uninfected patients with pulmonary tuberculosis. J Infect Dis 2001;183:1805-9.
75. Mayanja-Kizza H, Wajja A, Wu M, et al. Activation of beta-chemokines and CCR5 in persons infected with HIV type 1 and tuberculosis. J Infect Dis 2001;183:1801-4.
76. Mancino G, Placido R, Bach S, et al. Infection of human monocytes with Mycobacterium tuberculosis enhances HIV type 1 replication and transmission to T cells. J Infect Dis 1997;175:1531-5.
77. Ostrowski M, Krakauer D, Li Y, et al. Effect of immune activation on the dynamics of HIV replication and on the distribution of viral quasispecies. J Virol 1998;72:7772-84.
78. Mansky L, Temin H. Lower in vivo mutation rate of HIV type 1 than that predicted from the fidelity of purified reverse transcriptase. J Virol 1995;69:5087-94.
79. Jetzt A, Yu H, Klarmann G, Ron Y, Preston B, Dougherty J. High rate of recombination throughout the HIV type 1 genome. J Virol 2000;74:1234-40.
80. Ho D, Neumann A, Perelson A, Chen W, Leonard J, Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995;373:123-6.
81. Wei X, Ghosh S, Taylor M, et al. Viral dynamics in HIV type 1 infection. Nature 1995;373:117-22.
82. Carr J, Foley B, Leitner T, Salminen M, Korber B, McCutchan F. Reference sequences representing the principal genetic diversity of HIV-1 in the pandemic. In: B. K, C.L. K, B. F, et al., eds. Human retroviruses and AIDS. Vol. III:10-19. Los Alamos: Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, 1998.
83. Loussert-Ajaka I, Chaix M, Korber B, et al. Variability of HIV type 1 group O strains isolated from Cameroonian patients living in France. J Virol 1995;69:5640-9.
84. Quiñones-Mateu M, Albright J, Mas A, Soriano V, Arts E. Analysis of pol gene heterogeneity, viral quasispecies, and drug resistance in individuals infected with group O strains of HIV type 1. J Virol 1998;72:9002-15.
85. Simon F, Mauclere P, Roques P, et al. Identification of a new HIV type 1 distinct from group M and group O. Nat Med 1998;4:1032-7.
86. Roberson D, Anderson J, Bradac J, et al. HIV-1 nomenclature proposal: a reference guide to HIV-1 classification. In: B. K, C.L. K, B. F, et al., eds. Human retroviruses and AIDS. Los Alamos: Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, 1998:492-505.
87. Karlsson A, Lindback S, Gaines H, Sonnerborg A. Characterization of the viral population during primary HIV-1 infection. AIDS 1998;12:839-47.
88. Wolfs T, Zwart G, Bakker M, Goudsmit J. HIV-1 genomic RNA diversification following sexual and parenteral virus transmission. Virology 1992;189:103-10.
89. Wolinsky S, Wike C, Korber B, et al. Selective transmission of HIV type 1 variants from mothers to infants. Science 1992;255:1134-7.
90. Zhang L, MacKenzie P, Cleland A, Holmes E, Brown A, Simmonds P. Selection for specific sequences in the external envelope protein of HIV type 1 upon primary infection. J Virol 1993;67:3345-56.
91. Roos M, Lange J, de Goede R, et al. Viral phenotype and immune response in primary HIV type 1 infection. J Infect Dis 1992;165:427-32.
92. Zhu T, Mo H, Wang N, et al. Genotypic and phenotypic characterization of HIV-1 patients with primary infection. Science 1993;261:1179-81.
93. van't Wout A, Kootstra N, Mulder-Kampinga G, et al. Macrophagetrophic variants initiate HIV type 1 infection after sexual, parenteral, and vertical transmission. J Clin Invest 1994;94:2060-7.
94. Shankarappa R, Margolick J, Gange S, et al. Consistent viral evolutionary changes associated with the progression of HIV type 1 infection. J Virol 1999;73:10489-502.
95. Starcich B, Hahn B, Shaw G, et al. Identification and characterization of conserved and variable regions in the envelope gene of HTLV-III/LAV, the retrovirus of AIDS. Cell 1986;45:637-48.
96. Leonard C, Spellman M, Riddle L, Harris R, Thomas J, Gregory T. Assignment of intrachain disulfide bonds and characterization of potential glycosylation sites of the type 1 recombinant HIV envelope glycoprotein (gp120) expressed in Chinese hamster ovary cells. J Biol Chem 1990;265:10373-82.
97. Clerici M, Lucey D, Zajac R, et al. Detection of cytotoxic T lymphocytes specific for synthetic peptides of gp160 in HIV-seropositive individuals. J Immunol 1991;146:2214-9.
98. LaRosa G, Davide J, Weinhold K, et al. Conserved sequence and structural elements in the HIV-1 principal neutralizing determinant. Science 1990;249:932-5.
99. Korber B, Foley B, Kuiken C, Pillai S, Sodroski J. Numbering positions in HIV relative to HXB2CG. In: Myers G, Korber B, Hahn B, et al., eds. Human Retroviruses and AIDS. Los Alamos: Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, 1998;III:102-11.
100. Levy J. Pathogenesis of HIV infection. Ann N Y Acad Sci 1989;567:58-68.
101. Nei M, Gojobori T. Simple methods for estimating the numbers of synonymous and nonsynonymous nucleotide substitutions. Mol Biol Evol 1986;3:418-26.
102. Barker E, Mackewicz C, Reyes-Teran G, et al. Virological and immunological features of long-term HIV-infected individuals who have remained asymptomatic compared with those who have progressed to AIDS. Blood 1998;92:3105-14.
103. Bagnarelli P, Mazzola F, Menzo S, Montroni M, Butini L, Clementi M. Host-specific modulation of the selective constraints driving HIV type 1 env gene evolution. J Virol 1999;73:3764-77.
104. Markham R, Wang W, Weisstein A, et al. Patterns of HIV-1 evolution in individuals with differing rates of CD4 T cell decline. Proc Natl Acad Sci USA 1998;95:12568-73.
105. Nowak M, Anderson R, McLean A, Wolfs T, Goudsmit J, May R. Antigenic diversity thresholds and the development of AIDS. Science 1991;254:963-9.
106. McNearney T, Hornickova Z, Markham R, et al. Relationship of HIV type 1 sequence heterogeneity to stage of disease. Proc Natl Acad Sci USA 1992;89:10247-51.
107. Delwart E, Pan H, Sheppard H, et al. Slower evolution of HIV type 1 quasispecies during progression to AIDS. J Virol 1997;71:7498-508.
108. Lukashov V, Kuiken C, Goudsmit J. Intrahost HIV type 1 evolution is related to length of the immunocompetent period. J Virol 1995;69:6911-6.
109. Wolinsky S, Korber B, Neumann A, et al. Adaptive evolution of HIV type 1 during the natural course of infection. Science 1996;272:537-42.
110. Lukashov V, Goudsmit J. HIV heterogeneity and disease progression in AIDS: a model of continuous virus adaptation. AIDS 1998;12:43-52.
111. McGrath K, Hoffman N, Resch W, Nelson J, Swanstrom R. Using HIV-1 sequence variability to explore virus biology. Virus Res 2001;76:137-60.
112. Nakata K, Weiden M, Harkin T, Ho D, Rom W. Low copy number and limited variability of proviral DNA in alveolar macrophages from HIV-1-infected patients: evidence for genetic differences in HIV-1 between lung and blood macrophage populations. Mol Med 1995;1:744-57.
113. Itescu S, Simonelli P, Winchester R, Ginsberg H. HIV type 1 strains in the lungs of infected individuals evolve independently from those in peripheral blood and are highly conserved in the C-terminal region of the envelope V3 loop. Proc Natl Acad Sci USA 1994;91:11378-82.
114. Ait-Khaled M, McLaughlin J, Johnson M, Emery V. Distinct HIV-1 long terminal repeat quasispecies present in nervous tissues compared to that in lung, blood and lymphoid tissues of an AIDS patient. AIDS 1995;9:675-83.
115. Singh A, Besson G, Mobasher A, Collman R. Patterns of chemokine receptor fusion cofactor utilization by HIV type 1 variants from the lungs and blood. J Virol 1999;73:6680-90.
116. Strickland D, Kees U, Holt P. Regulation of T-cell activation in the lung: isolated lung T cells exhibit surface phenotypic characteristics of recent activation including down-modulated T-cell receptors, but are locked into the G0/G1 phase of the cell cycle. Immunology 1996;87:242-9.
117. Strickland D, Kees U, Holt P. Regulation of T-cell activation in the lung: alveolar macrophages induce reversible T-cell anergy in vitro associated with inhibition of interleukin-2 receptor signal transduction. Immunology 1996;87:250-8.
118. Rich E. Activation-inactivation of HIV-1 in the lung. J Biomed Sci 1998;5:1-10.
119. Honda Y, Rogers L, Nakata K, et al. Type I interferon induces inhibitory 16-kD CCAAT/ enhancer binding protein (C/EBP) beta, repressing the HIV-1 long terminal repeat in macrophages: pulmonary tuberculosis alters C/EBP expression, enhancing HIV-1 replication. J Exp Med 1998;188:1255-65.
120. Condos R, Rom W, Weiden M. Lung-specific immune response in tuberculosis. Int J Tuberc Lung Dis 2000;4:S11-7.
121. Koziel H, Kim S, Reardon C, et al. Enhanced in vivo human immunodeficiency virus-1 replication in the lungs of HIV-infected persons with Pneumocystis carinii pneumonia. Am J Respir Crit Care Med 1999;160:2048-55.
122. Dye C, Scheele S, Dolin P, Pathania V, Raviglione M. Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project. JAMA 1999;282:677-86.
123. Saks A, Posner R. Tuberculosis in HIV positive patients in South Africa: a comparative radiological study with HIV negative patients. Clin Radiol 1992;46:387-90.
124. Kramer F, Modilevsky T, Waliany A, Leedom J, Barnes P. Delayed diagnosis of tuberculosis in patients with HIV infection. Am J Med 1990;89:451-6.
125. Wong J, Ignacio C, Torriani F, Havlir D, Fitch N, Richman D. In vivo compartmentalization of HIV: evidence from the examination of pol sequences from autopsy tissues. J Virol 1997;71:2059-71.
126. Korber B, Kunstman K, Patterson B et al. Genetic differences between blood- and brain-derived viral sequences from HIV type 1-infected patients: evidence of conserved elements in the V3 region of the envelope protein of brain- derived sequences. J Virol 1994;68:7467-81.
127. Haggerty S, Stevenson M. Predominance of distinct viral genotypes in brain and lymph node compartments of HIV-1-infected individuals. Viral Immunol 1991;4:123-31.
128. Venturi G, Catucci M, Romano L, et al. Antiretroviral resistance mutations in HIV type 1 reverse transcriptase and protease from paired cerebrospinal fluid and plasma samples. J Infect Dis 2000;181:740-5.
129. Staprans S, Marlowe N, Glidden D, et al. Time course of cerebrospinal fluid responses to antiretroviral therapy: evidence for variable compartmentalization of infection. AIDS 1999;13:1051-61.
130. Coombs R, Speck C, Hughes J, et al. Association between culturable HIV-1 in semen and HIV-1 RNA levels in semen and blood: evidence for compartmentalization of HIV-1 between semen and blood. J Infect Dis 1998;177:320-30.
131. Delwart E, Mullins J, Gupta P, et al. HIV type 1 populations in blood and semen. J Virol 1998;72:617-23.
132. Quiñones-Mateu M, Ball S, Marozsan A, et al. A dual infection/competition assay shows a correlation between ex vivo HIV type 1 fitness and disease progression. J Virol 2000;74:9222-9233.
133. Escarmis C, Davila M, Charpentier N, Bracho A, Moya A,, Domingo E. Genetic lesions associated with Muller's ratchet in an RNA virus. J Mol Biol 1996;264:255-67.
134. Arias A, Lazaro E, Escarmis C, Domingo E. Molecular intermediates of fitness gain of an RNA virus: characterization of a mutant spectrum by biological and molecular cloning. J Gen Virol 2001;82:1049-60.
135. Clarke D, Duarte E, Moya A, Elena S, Domingo E, Holland J. Genetic bottlenecks and population passages cause profound fitness differences in RNA viruses. J Virol 1993;67:222-8.
136. Miralles R, Moya A, Elena S. Effect of population patchiness and migration rates on the adaptation and divergence of vesicular stomatitis virus quasispecies populations. J Gen Virol 1999;80 (Pt 8):2051-9.
137. Elena S, Gonzalez-Candelas F, Novella I, et al. Evolution of fitness in experimental populations of vesicular stomatitis virus. Genetics 1996;142:673-9.
138. Quiñones-Mateu M, Arts E. HIV-1 fitness: Implications for drug resistance, disease progression, and global epidemic evolution. HIV Sequence Compendium 2002 (in press).
139. Mammano F, Trouplin V, Zennou V, Clavel F. Retracing the evolutionary pathways of HIV type 1 resistance to protease inhibitors: virus fitness in the absence and in the presence of drug. J Virol 2000;74:8524-31.
140. Coffin J. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science 1995;267:483-9.